Phase Ib Clinical Study of Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Etoposide and Carboplatin for the First-line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Latest Information Update: 05 Jun 2024
At a glance
- Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Ivonescimab (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Akeso Biopharma
- 30 May 2024 Status changed from active, no longer recruiting to completed.
- 19 Sep 2023 Planned End Date changed from 1 May 2023 to 1 Apr 2024.
- 19 Sep 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Mar 2024.